UroGen Pharma (URGN) Other financing activities (2017 - 2026)
UroGen Pharma's (URGN) quarterly Other financing activities came in at $179000.0 in Q1 2026, up 496.67% YoY from $30000.0 in Q1 2025, and down 86.67% on a QoQ basis from $1.3 million in Q4 2025.
UroGen Pharma (URGN) Other financing activities (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Other financing activities data on file, last reported at $179000.0 in Q1 2026.
- Quarterly Other financing activities rose 496.67% year-over-year to $179000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 88.64% YoY) and the FY2025 annual result came in at $2.0 million, down 89.42% from the prior year.
- Other financing activities slipped to $179000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $47.9 million in Q3 2023 to a low of $16000.0 in Q2 2022.
- A 5-year average of $5.9 million and a median of $340000.0 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities soared 37133.33% — and 2025, when it slumped 98.41%.
- Tracing URGN's Other financing activities over 5 years: stood at $378000.0 in 2022, then jumped by 12568.25% to $47.9 million in 2023, then sank by 61.07% to $18.6 million in 2024, then slumped by 92.8% to $1.3 million in 2025, then sank by 86.67% to $179000.0 in 2026.
- The last three Other financing activities figures came in at $179000.0 (Q1 2026), $1.3 million (Q4 2025), and $302000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 887,000.00 |
| Jun 30, 2026 | 887,000.00 |
| Mar 31, 2026 | 179,000.00 |
| Mar 31, 2026 | 179,000.00 |
| Dec 31, 2025 | 1.34 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 302,000.00 |
| Sep 30, 2025 | 302,000.00 |
| Jun 30, 2025 | 297,000.00 |
| Jun 30, 2025 | 297,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Jun 30, 2024 | 18.64 Mn |
| Jun 30, 2024 | 18.64 Mn |
| Sep 30, 2023 | 47.89 Mn |
| Sep 30, 2023 | 47.89 Mn |
| Jun 30, 2023 | 143,000.00 |
| Jun 30, 2023 | 143,000.00 |
| Mar 31, 2023 | 671,000.00 |
| Mar 31, 2023 | 671,000.00 |